All In Biotech

Drug Trial Radar · NCT06475404

A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers

Open-label Multi-cohort Study of the Tolerability, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers After a Single Intravenous Injection in Increasing Doses

Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Apr 6, 2023

Primary completion

Sep 20, 2023

Study completion Sep 20, 2023

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers

Conditions

  • Mucopolysaccharidosis Type II
  • Metabolic Diseases

Interventions

  • verenafusp alfa 6 mg/kgBiological

    Single intravenous administration of 6 mg/kg of verenafusp alfa

  • verenafusp alfa 9 mg/kgBiological

    Single intravenous administration of 9 mg/kg of verenafusp alfa

  • verenafusp alfa 12 mg/kgBiological

    Single intravenous administration of 12 mg/kg of verenafusp alfa

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Adverse EventsTime frame: Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • State budgetary healthcare institution of the city of Moscow "City Clinic No. 2 of the Moscow Health Department"

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.